Baxter International Inc. acquired pharmacy technology company Baxa Corporation for $380 million, with corporate partner Roger Rhoten advising on the transaction.
The acquisition of Baxa supports Baxter's commitment to nutrition and patient safety, and enables the company to provide more solutions for the safe preparation and delivery of IV medications.